Epileptic Medication for CNS/ Neuromusc Dis: 70.8% of denials overturned
In 24 California IMR decisions from 2017 to 2025, reviewers overturned 17 (70.8%). In the last five years: 76.9% of 13. 23 were medical-necessity disputes, 1 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 3 | 100.0% |
| 2022 | 5 | 80.0% |
| 2023 | 1 | 0.0% |
| 2024 | 2 | 50.0% |
| 2025 | 2 | 100.0% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 18 | 72.2% | 70.8% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 4 | 75.0% | 70.8% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 3 | 33.3% | 70.8% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“Nature of Statutory Criteria/Case Summary: The parent of a patient has requested authorization and coverage for Valtoco nasal spray. Findings: The physician reviewer found that Current standards of care include providing rescue medications for patients at risk of status epilepticus or acute repetitive seizures. In this case, the patient has new onset epilepsy with convulsive seizures. Due to the epilepsy …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: The parent of a patient has requested authorization and coverage for Epidiolex (cannabidiol). Several studies have reviewed, and are supportive of, the safety and efficacy of Epidiolex for multiple epilepsy types. These studies have demonstrated reduction of up to 66% for all seizure types with Epidiolex use. In this case, …”
“Nature of Statutory Criteria/Case Summary: An enrollee’s parent has requested authorization and coverage for Fintepla. In this case, the patient has tried and failed several treatments. She is thus considered to have intractable generalized epilepsy, with limited treatment options. The patient has a photosensitive epilepsy known as Sunflower Syndrome. Current medical literature supports the use of fenfluramine, the ingredient in …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient requested authorization and coverage for clonazepam 1 mg orally disintegrating tablets (ODT) (12 tablets per 30 days).Epilepsy is a brain disorder that causes recurring, and unprovoked seizures. A review of medical literature establishes that the majority of seizures are controlled by one anti-seizure medication (ASM). Further, clonazepam is …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were Epileptic Medication denials for CNS/ Neuromusc Dis overturned?
In 24 California IMR decisions from 2017 to 2025, reviewers overturned 17 (70.8%). In the last five years: 76.9% of 13. 23 were medical-necessity disputes, 1 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.